Kornimate/medical-research-clean huggingface dataset:
effectiveness of physical therapy in stem cell transplant recipients for knee osteoarthritis

Conditions: Knee Osteoarthritis; Osteo Arthritis Knee; OA Knee

Summary: knee osteoarthritis has been considered as 11th highest contributor factor to nonfatal burdens in the world. it is considered one of the most common degenerative diseases of synovial joint and major cause of muscle impairment with limited functional activities. recent efforts to investigate the possibility of stem cell therapies in the treatment of symptomatic osteoarthritis have seen an increase in interest in regenerative medicine, fueled a better understanding of the role of mesenchymal stem cells. knee osteoarthritis is mostly managed by physical therapy, focused on managing pain, increasing the restricted range of motion and muscle strengthening. therefore, the hypothesis is that combining both treatments will be beneficial for patients. the aim of this randomized controlled trial is to evaluate the effectiveness of physiotherapy in mesenchymal stem cell recipient in improving pain, quadriceps muscle strength and functional status of knee osteoarthritis patients.

a single blinded rct will be conducted at ortho stem cell department, alkhaleej clinics. collection of data will be started after the scientific and ethical approval from dow university, karachi. after screening by physician and fulfilling the inclusion and exclusion criteria, patients (n=48) will be enrolled. after briefing about the objectives and obtaining formal consent, data will be collected. participants will be randomized and equally distributed into two groups i.e., twenty-four in control group '1' and twenty-four in treatment group '2'. the control group '1' will receive forward walking in home program after mesenchymal stem cell treatment while the treatment group '2' will be receiving quadriceps isometric exercise, straight limb raises (slr), hip isometric adductor, knee terminal extension, semi wall squat, quadriceps drill exercises for knee osteoarthritis after mesenchymal stem cell therapy. treatment plan will be of 8 weeks with 3 sessions in one week for 30 minutes. a physical therapist will do the assessment at baseline and at the end of treatment, other than the principal investigator to measure outcomes by using koos score, manual muscle testing and vas scale. for the completion of the study 6 months are required after synopsis approval.

Eligibility criteria:
inclusion criteria: * subjects of age 40 years and above. * male and female both will be included. * patients with single or both knee oa. * patients who had mesenchymal stem cell transplantation. * kellgren and lawrence grade ii, iii on radiological findings. exclusion criteria: * patients with any neurological disorder. * any musculoskeletal deformity (varus/valgus). * patients who have had any type of lower limb internal fixation. * patients who have had any type of lower limb arthroplasty or other knee surgery in the past. * patients with a history of any infectious or malignant condition.

Keywords: knee osteoarthritis mesenchymal stem cell treatment physiotherapy
efficacy, safety and tolerability of cadazolid in subjects with clostridium difficile associated diarrhea (cdad)

Conditions: Clostridium Difficile Infection

Summary: cadazolid is a new antibiotic developed for the treatment of clostridiun difficile associated diarrhea (cdad), also known as clostridium difficile infection (cdi). the purpose of the study was to evaluate the efficacy and safety of different doses of cadazolid in order to find the dose of cadazolid to be used for further clinical development of the compound in subjects with cdad.


Eligibility criteria:
key inclusion criteria: * male or female * at least 18 years of age * with a diagnosis of clostridium difficile-associated diarrhea (cdad): first occurrence or first recurrence. key exclusion criteria: * concurrent life threatening condition. * immuno-compromised subjects, concomittant immuno-suppresive treatment. * concomitant antimicrobial treatment for cdad. * any circumstances or conditions, which, in the opinion of the investigator, would affect full participation of the subject in the study or compliance with the protocol

Keywords: cdiff cdad cdi clostridium difficile infection
left ventricular pacing vectors effectiveness to narrow phrenic nerve stimulation

Conditions: Heart Failure

Summary: evaluation of three left ventricular pacing polarities effectiveness to narrow phrenic nerve stimulation.

the primary endpoint of the study aims at demonstrating that the three left ventricular polarities in the cardiac resynchronisation therapy-defibrillator could bypass phrenic nerve stimulation at least in 90% of implants. success was defined as an absence of phrenic nerve stimulation (threshold \> 7v) or in case of phrenic nerve stimulation occurrence (threshold \< 7v), as the resolution of the phrenic nerve stimulation by reprogramming one of the 3 left ventricular pacing polarities available in the device : left ventricular tip- left ventricular ring (bipolar), left ventricular tip- right ventricular ring (pseudo-bipolar) and left ventricular ring-right ventricular coil. any occurrence of phrenic nerve stimulation without resolution by reprogramming was considered as a failure.

Eligibility criteria:
inclusion criteria: * eligible for an implantation of a cardiac resynchronization therapy-defibrillator according to relevant regulations (will be only tolerated primo-implantation and upgrade) * patient scheduled for implantation of a cardiac resynchronization therapy-defibrillator * patient has given his informed consent exclusion criteria: * any contraindication for implantable cardioverter defibrillator therapy * heart transplantation or waiting for heart transplantation * implanted with a ventricular assist device (vad) * inability to understand the purpose of the study or to cooperate * not available for routine follow-up visits * life expectancy less than 12 months * age of less than 18 years and et pregnancy * under guardianship

Keywords: cardiac resynchronization therapy
bay12-8039, iv/oral pulmonary abscess/aspiration pneumonia

Conditions: Pneumonia, Aspiration; Lung Abscess

Summary: the purpose of this trial is to determine the efficacy and safety of moxifloxacin in comparison to sulbactam/ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years or above * the primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment exclusion criteria: * known hypersensitivity to fluoroquinolones and/or ß-lactams * patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis

Keywords: pulmonary abscess aspiration pneumonia
pharmacokinetic evaluation of moxifloxacin in vigadexa® in aqueous humor samples following preoperative antibiotic/steroid dosing in cataract surgery patients

Conditions: Cataract

Summary: the purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug vigadexa preoperatively in cataract patients.


Eligibility criteria:
inclusion criteria: * requires cataract surgery; * acceptable health status (medical history, physical, laboratory and ophthalmologic exams); * able to follow instructions and willing to attend all study visits; * other protocol-defined inclusion criteria may apply. exclusion criteria: * any known or suspected allergies/hypersensitivity to any of the investigational test product components; * history of invasive intraocular surgery in the eye to be operated, within 4 months before enrollment; * use of medications, as specified in protocol; * severe dry eye syndrome; * use of contact lenses two days before surgery until the last visit; * external eye disease, infection or inflammation of the eyes or eyelids; * excessive bleeding tendency; * no vision in the eye not included in the study; * pregnant or breastfeeding; * other protocol-defined exclusion criteria may apply.

Keywords: aqueous humor moxifloxacin vigadexa
early postnatal management of gestational brain sonographic malformations.

Conditions: Brain Abnormalities

Summary: gestational sonographic follow up may find some brain malformations. the trial is about to characterize these findings and correlate with the immediate postnatal findings.

gestational sonographic follow up may find some brain malformations (such as ventricular enlargement, agenesis of corpus callosum, etc.).the trial is about to characterize these findings and correlate with the immediate postnatal findings.

Eligibility criteria:
inclusion criteria: * all term newborn infants who underwent a neurologic consultation or brain ultrasound. exclusion criteria: * prematurity
study of dasatinib in children and adolescents with relapsed or refractory leukemia

Conditions: Leukemia

Summary: the purpose of this clinical research study was to establish a recommended phase 2 once daily (qd) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous treatment) leukemia in children and adolescents. the side effects that this oral investigational drug may have in children, and the levels of the drug in the blood, will be studied at different doses.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * ph-positive (ph+) chronic myelogenous leukemia in chronic, accelerated or blast phase or ph+ acute lymphoblastic leukemia (all) with imatinib-resistant disease or intolerance to imatinib. * ph-negative acute leukemia in second or subsequent relapse * age \>1 and \<21 years * lansky or karnofsky scale \>60 * life expectancy \>3 weeks * adequate hepatic and renal function * written informed consent exclusion criteria: * subjects for whom potentially-curative therapy was available, including electing immediate \[ie, planned \<45 days\] stem-cell transplantation. subjects in stratum 1 were to have had an ongoing identical hla donor search, and may have discontinued study if a donor became available.) * subjects with symptomatic central nervous system (cns) disease (eg, convulsions due to their cns disease). * subjects who had not recovered from acute toxicity of previous therapy. * clinically-significant disorder of platelet function (eg, von willebrand's disease) or ongoing gastrointestinal bleeding. * serious uncontrolled medical disorder or active infection * uncontrolled or significant cardiovascular disease * use of any investigational agent or any other anticancer agent within 14 days prior to treatment start. * prior therapy with dasatinib * subjects taking medications that irreversibly inhibit platelet function or anticoagulants. * subjects taking certain medications that are accepted to have a risk of causing qtc prolongation. * women of child bearing potential with a positive pregnancy test prior to study drug administration. * expected noncompliance, or unable to have regular follow-up due to psychologic, social, familial, or geographic reasons. * subjects who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (eg, infectious disease) illness must not be enrolled into this study.

Keywords: relapsed and refractory leukemia
assessment of anterior chamber configuration changes after phacoemulsification

Conditions: Cataract; Shallow Anterior Chamber; Narrow Angle

Summary: to investigate changes in anterior chamber angle configuration after phacoemulsification and intraocular lens (iol) implantation with swept-source optical coherence tomography (ss-oct).

to investigate changes in anterior chamber angle configuration after phacoemulsification and intraocular lens (iol) implantation in eyes with a shallow anterior chamber and narrow angle, compared with the eyes with normal anterior chamber and open angle using swept-source optical coherence tomography (ss-oct).

Eligibility criteria:
inclusion criteria: acd was less than 2.68mm. the anterior chamber angle width on gonioscopy≤shaffer 2 . exclusion criteria: primary or secondary glaucoma, peripheral anterior synechiae, history of ocular surgeries

Keywords: shallow anterior chamber narrow angle ss-oct
effectiveness of generic versus reference cetrorelix acetate for ovarian stimulation using a gonadotropin-releasing hormone（gnrh）antagonist protocol in women undergoing ivf

Conditions: Infertility

Summary: the goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a gnrh antagonist protocol for ovarian stimulation in women undergoing ivf or intracytoplasmic sperm injection(icsi) treatment.the main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the gnrh antagonist based protocol for women undergoing ivf. ovarian stimulation was achieved by several types of follicle-stimulating hormone(fsh) or by fsh combined with luteinizing hormone activity. daily dose of generic cetrorelix acetate (0.25 mg sc) or original cetrorelix acetate (0.25 mg sc) will be administered when the lead follicle was 14 mm. when more than two follicles reached 17 mm, oocyte maturation was triggered with 250 mcg of recombinant human chorionic gonadotropin.


Eligibility criteria:
inclusion criteria: * infertile couples plan to undergo ivf / icsi pregnancy treatment into screening procedures and clinical study 1. all subjects should sign the informed consent form 2. infertile women \<43 years old 3. with flexible gnrh antagonist exclusion criteria: * subjects could not enter the study if they meet any one of the following criteria 1. preimplantation genetic testing (pgt) 2. untreated hydrosalpinges, moderate or severe endometriosis, recurrent spontaneous miscarriage, endometrial pathology, uterine malformations, etc 3. endocrine diseases (such as hyperthyroidism, hyperprolactinemia, etc.) or other systemic disease and other systemic diseases (such as hypertension, diabetes, etc.)． 4. other factors were considered inappropriate by the investigator to participate, or assisted reproductive technology/pregnancy contraindications
combination plant-based protein and marine-based multi-mineral supplement and bone remodeling in young adults

Conditions: Bone Resorption; Bone and Bones

Summary: nutrient intake of calcium and protein are known to function as regulators of bone remodeling. specifically, a balanced rate of bone resorption and bone formation (i.e. bone remodeling process) is required to maintain bone health. however, a high remodeling rate, or an imbalance between formation and resorption, as well as suboptimal nutrient intake are known to contribute to fracture risk and bone dysfunction. gut-derived hormones represent an important link between nutrient intake and bone remodeling (i.e. gut-bone axis). a sustainable nutritional intervention that positively modulates the postprandial responses of gut-derived hormones and the linked bone remodeling processes is an attractive option for the optimization of bone health in young adults. the proposed nutrient intervention seeks to explore the bioefficacy of a combination plant-based protein and marine-based multi-mineral supplement following oral ingestion in young, healthy men and women. a postprandial time-course study will be undertaken to examine the acute effects and/or associations between different gut-derived hormones and biomarkers of bone metabolism.

a block-randomized, within-subject, two-day, crossover design examining acute (0-4 hour) postprandial changes in different gut-derived hormone concentrations and biomarkers of bone metabolism in 12 healthy, young adults following ingestion of a combination plant-based protein and marine-based multi-mineral supplement or control. each participant will consume (in a random manner) either one of two investigational products (i.e., combined nutritional supplement or control). the combined nutritional supplement will consist of: 0.3 g/kg body mass of atura fava-bean protein and 800mg of aquamin f (a highly bioactive source of minerals rich in calcium) dissolved in 500ml water volume. the control product will consist of 500ml water volume without the protein and multi-mineral nutritional composition.

Eligibility criteria:
inclusion criteria: * men and women aged 18 to 35 years. * recreationally active (150-300 min/week of moderate physical activity). * healthy (i.e.,not presenting with injury, illness, medication, history of chronic disease, or known allergies/intolerance (e.g. favism) to the ingredients contained in either formulation.

Keywords: nutrition plant marine protein bone skeletal health dietary supplements sustainable
effectiveness of a proprioceptive neuromuscular proprioceptive neuromuscular facilitation

Conditions: Proprioceptive Neuromuscular Facilitation

Summary: introduction: paddle tennis is a popular sport which can cause lower limb injuries due to impaired flexibility, such as ankle dorsiflexion. to improve this, methods such as proprioceptive neuromuscular facilitation (pnf), eccentric exercises and electrical stimulation (nmes) can be used. objective: to compare the effectiveness of a pnf program with one of eccentric exercise plus nmes in the weight bearing lunge, lateral step down and drop jump test in amateur paddle tennis players. methods: pilot randomized clinical trial involving 20 male amateur paddle tennis players. participants were randomly divided into two groups of ten. one group received a pnf protocol, while the another group was given an eccentric+ nmes exercise protocol. during the study, range of dorsal ankle flexion (romdf) was measured, as well as the vertical jump and lateral step down capacity of the participants.


Eligibility criteria:
inclusion criteria: * be a professional padel player. * be over 18 years of age. * sign the informed consent to participate in the study. * completion of the ipaq physical activity questionnaire (annex 1) to assess the level of physical activity of the participants and to ensure that they meet the physical activity level of the participants and to ensure that they meet the requirements for requirements for participation in the study. exclusion criteria: * traumatic or musculoskeletal history that may affect the performance of the study exercises, as determined in the exercises of the study. * a neurological history that may cause impairment in the performance of the exercises. * use of orthoses that may generate alterations in the result. * difficulty in performing exercises as determined by the physical activity readiness questionnaire (par-q)

Keywords: proprioceptive neuromuscular facilitation; paddle tennis ankle dorsiflexion range eccentric exercise neuromuscular electrostimulation
safety & efficacy of pegolsihematide for treatment of anemia in participants on dialysis

Conditions: Chronic Renal Failure; Anemia; Dialysis

Summary: the purpose of this study is to evaluate the safety and efficacy of multiple intravenous doses of pegol-sihematide in participants with chronic kidney disease (ckd) who are on dialysis.


Eligibility criteria:
inclusion criteria: 1. males or females≥18 and≤70, weight ≥ 45 kilograms (kg) 2. participants with chronic renal failure on dialysis for ≥ 3 months prior to randomization. 3. on esas treatment for ≥8 weeks prior to randomization with stable doses and the average doses ≤ 10000 iu/week 4. hemoglobin values of ≥ 10.0 and≤ 12.0 g/dl at screening 5. patients with a transferrin saturation≥ 20% and a ferritin≥ 100 ng/ml. vitamin b12 and folic acid level above lower limit of normal. 6. signed informed consent exclusion criteria: 1. pregnant or lactating females 2. red blood cell transfusion within 3 months prior to randomization 3. known intolerance to any erythropoiesis stimulating agent (esa) or pegylated molecule or to all parenteral iron supplementation products 4. hemolytic syndromes or coagulation disorder 5. hematological disease (including but not limited to myelodysplastic syndrome, hematological malignancy, , hemoglobinopathy, pure red cell aplasia), 6. chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.); 7. c reactive protein (crp) greater than 30 mg/l within the 4 weeks prior to randomization 8. uncontrolled or symptomatic secondary hyperparathyroidism(ipth\>800pg/ml) 9. poorly controlled hypertension within 4 weeks prior to randomization 10. chronic congestive heart failure (new york heart association class ⅲ or iv) 11. significant symptom within 6 months prior to randomization (e.g. myocardial infarction, serious or precarious coronary artery disease,stroke, respiratory disease, autoimmune disease, neuropathy, phrenopathy, hepatopathy including active hepatitis b, active hepatitis c, a positive test for hiv antibody or alt\> 2 x upper limit of normal (uln), ast\> 2 x upper limit of normal (uln)) 12. tumor malignancy 13. expected survival less than 12 months 14. a scheduled kidney transplant 15. major surgery (may massive bleeding) during the study 16. expected conception within 4 weeks after the end of the study treatment 17. the subject has participated in other clinical trial within the 12 weeks prior to randomization 18. have any other condition or prior therapy that, in the investigator's opinion, would make the subject unsuitable for the study, or unable or unwilling to comply with the study procedures

Keywords: esas ckd
efavirenz in treating patients with metastatic prostate cancer

Conditions: Prostate Cancer

Summary: rationale: efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. purpose: this phase ii trial is studying how well efavirenz works in treating patients with metastatic prostate cancer.

objectives: primary * to assess the effect of efavirenz on the psa non-progression rate at 3 months in patients with castration-refractory metastatic prostate cancer. secondary * to assess the effect of efavirenz on the psa non-progression rate at 6 months. * to assess the effect of efavirenz on overall survival. * to assess the effect of efavirenz on psa progression-free survival.. * to assess the tolerability and safety profile of efavirenz. outline: this is a multicenter study. patients receive oral efavirenz once daily in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
disease characteristics: * histologically confirmed prostate cancer * metastatic disease * castration-refractory disease * no clinical symptoms related to disease progression patient characteristics: * who performance status 0-2 prior concurrent therapy: * not specified

Keywords: recurrent prostate cancer stage iv prostate cancer